Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

By Mariam Sunny and Mrinalika Roy Aug 4 (Reuters) – Pfizer reported better-than-expected second-quarter results on Tuesday, powered by strong demand for blood thinner Eliquis and recently acquired

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)